格隆汇1月30日丨美迪西(688202.SH)公布，经公司财务部门初步测算，预计2025年度将出现亏损，公司 实现归属于母公司所有者的净利润为-18,600万元到-12,400万元，与上年同期（法定披露数据）相比， 亏损预计减少14,485万元到20,685万元，同比减亏43.78%至62.52%。预计2025年年度实现归属于母公司 所有者的扣除非经常性损益后的净利润为-20,400万元到-13,600万元，与上年同期（法定披露数据）相 比，亏损预计减少14,371万元到21,171万元，同比减亏41.33%至60.89%。 报告期内，公司归属于母公司所有者的净利润以及归属于母公司所有者的扣除非经常性损益后的净利润 较上年同期实现大幅减亏，主要系公司加快全球化战略布局，充分发挥研发平台资源和优势，实现营业 收入预计同比增长约12%，其中境外主营业务收入占比预计提升至约47%。公司在推动营业收入增长的 同时，持续深化降本增效，加强成本管控，综合毛利率预计同比提升约11个百分点，盈利能力稳步改 善，实现亏损规模大幅收窄。 ...

格隆汇1月30日丨美迪西(688202.SH)公布，经公司财务部门初步测算，预计2025年度将出现亏损，公司 实现归属于母公司所有者的净利润为-18,600万元到-12,400万元，与上年同期（法定披露数据）相比， 亏损预计减少14,485万元到20,685万元，同比减亏43.78%至62.52%。预计2025年年度实现归属于母公司 所有者的扣除非经常性损益后的净利润为-20,400万元到-13,600万元，与上年同期（法定披露数据）相 比，亏损预计减少14,371万元到21,171万元，同比减亏41.33%至60.89%。 报告期内，公司归属于母公司所有者的净利润以及归属于母公司所有者的扣除非经常性损益后的净利润 较上年同期实现大幅减亏，主要系公司加快全球化战略布局，充分发挥研发平台资源和优势，实现营业 收入预计同比增长约12%，其中境外主营业务收入占比预计提升至约47%。公司在推动营业收入增长的 同时，持续深化降本增效，加强成本管控，综合毛利率预计同比提升约11个百分点，盈利能力稳步改 善，实现亏损规模大幅收窄。 ...

（记者 王晓波） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 每经AI快讯，美迪西1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为-1.86亿元到-1.24亿元，与上年同期相比，亏损预计减少约1.45亿元~2.07亿元，同比减亏 43.78%~62.52%。业绩变动主要原因是，报告期内，公司归属于母公司所有者的净利润以及归属于母公 司所有者的扣除非经常性损益后的净利润较上年同期实现大幅减亏，主要系公司加快全球化战略布局， 充分发挥研发平台资源和优势，实现营业收入预计同比增长约12%，其中境外主营业务收入占比预计提 升至约47%。公司在推动营业收入增长的同时，持续深化降本增效，加强成本管控，综合毛利率预计同 比提升约11个百分点，盈利能力稳步改善，实现亏损规模大幅收窄。 ...

美迪西1月30日公告，预计2025年度归母净利润亏损1.24亿元-1.86亿元，上年同期亏损3.31亿元。该公 司称，报告期内，公司归属于母公司所有者的净利润较上年同期实现大幅减亏，主要系公司加快全球化 战略布局，充分发挥研发平台资源和优势，实现营业收入预计同比增长约12%，其中境外主营业务收入 占比预计提升至约 47%。公司在推动营业收入增长的同时，持续深化降本增效，加强成本管控，综合 毛利率预计同比提升约11个百分点，盈利能力稳步改善，实现亏损规模大幅收窄。 ...

证券代码：688202 证券简称：美迪西 公告编号：2026-003 上海美迪西生物医药股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 经上海美迪西生物医药股份有限公司（以下简称"公司"）财务部门初步 测算，预计 2025 年度将出现亏损，公司实现归属于母公司所有者的净利润为 -18,600 万元到-12,400 万元，与上年同期（法定披露数据）相比，亏损预计减少 14,485 万元到 20,685 万元，同比减亏 43.78%至 62.52%。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益后的净利 润为-20,400 万元到-13,600 万元，与上年同期（法定披露数据）相比，亏损预计 减少 14,371 万元到 21,171 万元，同比减亏 41.33%至 60.89%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （三）本次业绩预告未经注册会计师审计。 二、上 ...

声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 第1笔成交价格为51.50元，成交16.00万股，成交金额824.00万元，溢价率为-13.55%，买方营业部为国 泰海通证券股份有限公司杭州学院路证券营业部，卖方营业部为中国银河证券股份有限公司北京苏州街 证券营业部。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为824万元。该股近5个交易日累计下 跌5.40%，主力资金合计净流出2038.53万元。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 1月29日，美迪西收涨1.41%，收盘价为59.57元，发生1笔大宗交易，合计成交量16万股，成交金额824 万元。 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-29 | 美迪西 | 688202 | 51.5 824 | 16 | 国泰海通证券股份 有限公司杭州学院 | 中国银河证券股份 有限公司北京苏州 | | 1月29日，美迪西大宗交易成交16万股，成交额824万元，占当日总成交额的3.48%，成交价51.5元，较市场收盘价59.57元折价13.55%。 ...

Market Overview - The medical services sector experienced a decline of 1.41% on January 26, with Meidisi leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] Stock Performance - Notable gainers in the medical services sector included: - Guangzheng Eye Hospital (002524) with a closing price of 5.05, up 10.02% on a trading volume of 266,400 shares and a transaction value of 132 million [1] - Lanwei Medical (301060) closed at 12.28, up 3.98% with a trading volume of 325,000 shares and a transaction value of 392 million [1] - Major decliners included: - Meidisi (688202) closed at 60.88, down 7.28% with a trading volume of 71,600 shares and a transaction value of 444 million [2] - Meinian Health (002044) closed at 7.26, down 6.08% with a trading volume of 3.7675 million shares and a transaction value of 2.776 billion [2] Capital Flow - The medical services sector saw a net outflow of 1.318 billion from institutional investors, while retail investors had a net inflow of 1.011 billion [2] - The capital flow for specific stocks showed: - Boteng Co. (300363) had a net outflow of 39.83 million from institutional investors [3] - Guangzheng Eye Hospital (002524) had a net inflow of 39.29 million from institutional investors [3] - Lanwei Medical (301060) had a net inflow of 24.71 million from institutional investors [3]

Group 1 - Spot gold price has surpassed $5000 per ounce for the first time, with institutions predicting it could rise to $6600 [2] - The recent surge in gold prices is attributed to U.S. President Trump's policies reshaping international relations and investors fleeing sovereign bonds and foreign exchange markets [2] - Last week, gold prices increased by 8.5%, driven by a weakening dollar, which has made gold and silver cheaper for global buyers [2] Group 2 - In the past two weeks, stock ETFs have seen a net outflow of nearly 500 billion yuan, with significant redemptions in broad-based ETFs [3] - The trading volume of stock ETFs has surged, with some broad-based ETFs reaching record highs since their inception [3] Group 3 - The semiconductor sector in A-shares has been active in mergers and acquisitions, with several companies announcing related plans and progress [8] Group 4 - The commercial aerospace sector is experiencing a talent shortage, with investors with relevant experience being highly sought after [9] - The market is facing a significant gap in experienced commercial aerospace investors, leading firms to recruit candidates with adjacent experience [9] Group 5 - Global commodity markets are entering a new super cycle, with fund managers strategically increasing allocations to non-ferrous and chemical products [10] - Factors such as global monetary expansion, a credit crisis in the dollar, and geopolitical conflicts are contributing to this anticipated cycle [10]

Core Viewpoint - The major shareholder of Shanghai Medicilon Inc., Chen Guoxing, has decided to terminate his share reduction plan early, maintaining his current holdings due to confidence in the company's stable development and changes in personal financial needs [3][6]. Shareholder Holdings - Before the reduction plan, Chen Guoxing held 4,875,154 shares, accounting for 3.63% of the total share capital, while his concerted action partner, Lin Changqing, held a total of 8,806,324 shares, representing 6.55% of the total share capital [2][8]. Reduction Plan Implementation Results - On November 20, 2025, Chen Guoxing announced a plan to reduce his holdings by up to 2,200,000 shares (1.64% of total share capital) within three months, but as of the announcement date, he had not executed any reductions and still held 4,875,154 shares [3][6]. - The decision to terminate the reduction plan was based on Chen's confidence in the company's ongoing stability and changes in his financial situation [3][6]. Future Shareholding Intentions - Following the completion of the reduction plan, Lin Changqing intends to continue holding his shares and will consider reducing his holdings based on personal development needs while adhering to relevant laws and commitments [9][10].